Adiposopathy is a more rational treatment target for metabolic disease than obesity alone

被引：34

作者：

Bays H. ^{[1
]}

Dujovne C.A. ^{[1
]}

机构：

[1] L-MARC Research Center, Louisville, KY 40213

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 2期

关键词：

Orlistat; Rimonabant; Sibutramine; Antiobesity Agent; Tesaglitazar;

D O I：

10.1007/s11883-006-0052-6

中图分类号：

学科分类号：

摘要：

Current guidelines recommend that weight-loss therapy should be primarily based upon specific body mass index (BMI) cut-off limits. However, in the adipocentric paradigm, it is acknowledged that co-morbidities, such as type 2 diabetes mellitus, hypertension, and dyslipidemia, occur at all levels of BMI. Excessive fat mass (adiposity) in genetically susceptible individuals results in fat dysfunction (adiposopathy), which then contributes to metabolic disorders that increase the risk of atherosclerotic cardiovascular disease. In this paradigm, the term "anti-obesity" treatment might best be replaced by "anti-adiposopathy" treatment, wherein the focus is not based solely on BMI, but instead directed towards physiologically improving fat cell function and clinically improving the metabolic health of patients, This may occur through appropriate diet, physical exercise, and other lifestyle changes, and/or from drug therapies. Cannabinoid receptor antagonists and peroxisome proliferator activated receptor agonists are examples of agents that physiologically improve fat function and clinically improve metabolic disease. Copyright © 2006 by Current Science Inc.

引用

页码：144 / 156

页数：12

共 125 条

[1] Bays H., Abate N., Chandalia M., Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia, Future Cardiol, 1, pp. 39-59, (2005)
[2] Kershaw E.E., Flier J.S., Adipose tissue as an endocrine organ, J Clin Endocrinol Metab, 89, pp. 2548-2556, (2004)
[3] Bays H., Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything, Expert Rev Cardiovasc Ther, 3, pp. 393-404, (2005)
[4] Kahn R., Buse J., Ferrannini E., Stern M., The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 28, pp. 2289-2304, (2005)
[5] Stern M.P., Williams K., Gonzalez-Villalpando C., Et al., Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?, Diabetes Care, 27, pp. 2676-2681, (2004)
[6] The practical guide to the identification, evaluation and treatment of overweight and obesity in adults, (2005)
[7] Snow V., Barry P., Fitterman N., Et al., Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians, Ann Intern Med, 142, pp. 525-531, (2005)
[8] Grundy S.M., What is the contribution of obesity to the metabolic syndrome?, Endocrinol Metab Clin North Am, 33, pp. 267-282, (2004)
[9] Franks P.W., Brage S., Luan J., Et al., Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity, Obes Res, 13, pp. 1476-1484, (2005)
[10] Karelis A.D., St-Pierre D.H., Conus F., Et al., Metabolic and body composition factors in subgroups of obesity: What do we know?, J Clin Endocrinol Metab, 89, pp. 2569-2575, (2004)

← 1 2 3 4 5 6 7 8 9 10 →